Form 4: Vera Therapeutics Director Acquires Stock Options

James R. Meyers, a Director at Vera Therapeutics, Inc., acquired 17,084 stock options with an exercise price of $34.35, vesting in full on May 20, 2036, or earlier upon a change in control.

Summary

• James R. Meyers, a Director of Vera Therapeutics, Inc. (VERA), reported the acquisition of stock options on May 21, 2026.
• The options grant the right to purchase Class A Common Stock at an exercise price of $34.35 per share.
• A total of 17,084 stock options were acquired.
• These options are set to vest in full on May 20, 2036, or earlier if a change in control occurs, provided continuous service is maintained.
• The reporting person, James R. Meyers, is listed as a Director and not a 10% owner or officer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While director option grants can be positive, the high exercise price relative to potential current market value and the long vesting period suggest the immediate impact is limited, and the value is purely speculative on future performance.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The vesting schedule tied to a future date and potential change in control aligns management incentives with long-term shareholder value.

Negatives

• The exercise price of $34.35 is significantly higher than the current market price (as of the filing date, implied by the nature of Form 4 filings for options). This suggests the options are currently out-of-the-money.
• No new capital is being injected into the company through this transaction; it's an equity grant.

Risks

• The value of the acquired options is contingent on the company's stock price appreciating significantly above the $34.35 exercise price by the vesting date or a change in control event.
• If the company's stock price does not increase, the options may expire worthless.
• The vesting is subject to the reporting person's continuous service, meaning departure from the company before vesting would result in forfeiture.

Future Outlook

The future outlook for the acquired options is dependent on the company's stock performance and potential change in control events. The options are exercisable at $34.35 and vest fully by May 20, 2036, or upon a change in control.

Management Comments

• The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
• Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with long-term company performance and shareholder value, especially for growth-stage companies like Vera Therapeutics.

Stakeholder Impact

• Shareholders: The grant of options to a director, while common, does not immediately dilute share value but represents potential future dilution if exercised. It aligns director incentives with stock appreciation.
• Employees: This filing does not directly impact employees, but it reflects a compensation strategy that may be mirrored in employee option grants.
• Management: Reinforces the alignment of director compensation with company performance and shareholder value.

Next Steps

• Continuous service by James R. Meyers through the vesting dates or a change in control event.
• Potential exercise of stock options if the stock price exceeds $34.35 by the vesting date or upon a change in control.

Key Dates

Keywords

Vera Therapeutics, VERA, Form 4, Stock Options, Director, Beneficial Ownership, Securities Exchange Act, Equity Grant, Vesting Schedule